109 results
8-K
EX-99.1
ANNX
Annexon Inc
25 Jun 24
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
5:14pm
patients to get better sooner, which translated into continued long-term benefits and a significantly higher likelihood of full recovery versus placebo … are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data
8-K
EX-99.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept
8-K
EX-1.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
” (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan exceeds the present value of all benefits … benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering of the Offered Securities or (ii) if the allocation
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
regarding their entitlement to benefits under any applicable income tax treaty.
Exercise of pre-funded warrants
A non-U.S. holder generally … of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate
FWP
ANNX
Annexon Inc
5 Jun 24
Free writing prospectus
7:56pm
for certain items. Non-U.S. holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty
424B5
7snlbmhu0 4j3
4 Jun 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
iopf6x h1
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
8-K
EX-99.1
rvaahvjps wtm1
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
sgix650
7 May 24
Other Events
4:05pm
424B5
2sxrxobgmqhj
5 Apr 24
Prospectus supplement for primary offering
4:07pm